Skip to content

Cash ratio at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
2.3×+0.8×
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
2.3×+0.9×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
3.8×-2.3×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
3.4×0.0×
Nuvation Bio logo
Nuvation BioNUVB
1.6×+0.7×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
0.5×+0.1×

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$1.95B+40.1%
Enterprise value$1.94B+45.1%
P/S27.2×+2.5×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Calculated from Nurix Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s cash ratio?
Nurix Therapeutics, Inc. (NRIX) reported cash ratio of 0.8× in Q4 2025.
How has Nurix Therapeutics, Inc.'s cash ratio changed year-over-year?
Nurix Therapeutics, Inc.'s cash ratio decreased by 8.3% year-over-year, from 0.9× to 0.8×.
What is the long-term trend for Nurix Therapeutics, Inc.'s cash ratio?
Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s cash ratio has grown at a 1.4% compound annual growth rate (CAGR), from 2.7× to 2.9×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.